Trial reportNature medicine2018
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482059 (A Multicenter Phase Ib/II Clinical Study on the Safety and Efficacy of Selective Internal Radiation Therapy), which is not on this map. Cited by 554 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
554citing papers in PubMed, 2 pooled it
34.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07482059 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation
A Multicenter Phase Ib/II Clinical Study on the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Microspheres in Combination With Nivolumab, Ipilimumab, and Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
Who cites it
554 citing papers in PubMed, 2 syntheses or guidelines pooled it, 907 citations in OpenAlex.
- The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.Journal for immunotherapy of cancer · 2026Trial
- Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety.Radiation oncology (London, England) · 2026Trial
- PEGylated IL2 and tumor-targeted radiotherapy augment CD8Theranostics · 2026Trial
- Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.Nature cancer · 2025Trial
- Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer.Journal for immunotherapy of cancer · 2025Trial
- Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.Signal transduction and targeted therapy · 2025Trial
- Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).Nature cancer · 2025Trial
- A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.Frontiers in immunology · 2025Trial
- Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.Journal for immunotherapy of cancer · 2024Trial
- Trial
- Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.Cancer immunology, immunotherapy : CII · 2024Trial
- [Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Trial
- First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.Journal for immunotherapy of cancer · 2023Trial
- Upfront or deferred radiotherapy combined with chemoimmunotherapy for inoperable oesophageal squamous cell carcinoma: a target trial emulation in China.EClinicalMedicine · 2026Article
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Radiation-Triggered Chemokine-Secreting Probiotics for Boron Neutron Capture Therapy Based Radioimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.The Journal of clinical investigation · 2026Review
494 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 7 institutions in 1 country.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. formenti@med.cornell.edu.ORCID http://orcid.org/0000-0002-8227-8924
Nils-Petter RudqvistDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9720-3124
Encouse GoldenDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Benjamin CooperDepartment of Radiation Oncology, New York University School of Medicine, New York, NY, USA.
Erik WennerbergDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Claire LhuillierDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Claire Vanpouille-BoxDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-7213-0670
Kent FriedmanDepartment of Radiology, New York University School of Medicine, New York, NY, USA.
Lucas Ferrari de AndradeDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Adriana HeguyDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Naoko ImaiTisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sacha GnjaticTisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5643-9520
Ryan O EmersonAdaptive Biotechnologies, Seattle, WA, USA.
Xi Kathy ZhouDivision of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8942-439X
Tuo ZhangDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-5396-918X
Abraham ChachouaDepartment of Medicine, New York University School of Medicine, New York, NY, USA.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. szd3005@med.cornell.edu.ORCID http://orcid.org/0000-0003-4426-0499
Cornell University · USNew York University · USHarvard University · USIcahn School of Medicine at Mount Sinai · USAdaptive Biotechnologies (United States) · USNew York Genome Center · USUniversity of California, San Francisco · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MReprogramming of T cells for the Treatment of MelanomaR01CA173750 · NCI · DANA-FARBER CANCER INST · PI GOTTSCHALK, STEPHEN, WUCHERPFENNIG, KAI W · 2012 to 2016
$5.0MCancer Cell Intrinsic Interferon-I pathway Activation by Fractionated RadiationR01CA201246 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEMARIA, SANDRA · 2016 to 2025
$3.9MIndividualized in situ vaccination by radiation and immunotherapyR01CA198533 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEMARIA, SANDRA · 2016 to 2020
$1.9MNCI NIH HHS P30 CA016087NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA173750NCI NIH HHS R01 CA198533NCI NIH HHS R01 CA201246
Abstract
Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in preclinical studies and in some patients with melanoma
Indexed as
AgedAged, 80 and overAntibodies, MonoclonalCD8-Positive T-LymphocytesCell Line, TumorCombined Modality TherapyCTLA-4 AntigenDrug Resistance, NeoplasmFemaleHumansIpilimumabLung NeoplasmsMaleMiddle AgedRadiotherapyAntibodies, MonoclonalCTLA-4 AntigenCTLA4 protein, humanIpilimumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07482059ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.